5 active not recruiting, 3 completed, 1 recruiting. 9 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Active not recruiting 5, Completed 3, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
Follow Refractory Peripheral Primitive Neuroectodermal Tumor: new trials by email Literature Review of Refractory Peripheral Primitive Neuroectodermal Tumor trials Research Report on Refractory Peripheral Primitive Neuroectodermal Tumor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-11-13 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-11-13 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-11-13 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-11-13 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) Tazemetostat - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Hodgkin Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 20 | 2017-11-13 | 2026-04-13 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors Bevacizumab, Irinotecan Hydrochloride, Temozolomide - Central Nervous System Neoplasm, Pineoblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 108 | 2010-11-22 | 2021-07-23 |
Neuroectodermal Tumors, Primitive, Peripheral (9) · Hepatoblastoma (8) · Medulloblastoma (8) · Neuroblastoma (8) · Osteosarcoma (8) · Rhabdoid Tumor (8) · Rhabdomyosarcoma (8) · Sarcoma (8) · Sarcoma, Ewing (8) · Wilms Tumor (8) · Ependymoma (7) · Glioma (7) · Histiocytosis, Langerhans-Cell (7) · Lymphoma, Non-Hodgkin (7) · Central Nervous System Neoplasms (3)
Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Germ Cell and Embryonal (9) · Neoplasms, Glandular and Epithelial (9) · Neoplasms, Nerve Tissue (9) · Neoplasms, Neuroepithelial (9) · Neuroectodermal Tumors (9) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (8) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Genetic Diseases, Inborn (8) · Kidney Diseases (8) · Kidney Neoplasms (8) · Male Urogenital Diseases (8) · Myosarcoma (8)
Magnetic Resonance Spectroscopy (2) · Nuclear Medicine Department, Hospital (2) · Phantoms, Imaging (2) · Temozolomide (2) · X-Rays (2) · ivosidenib (2) · palbociclib (2) · selpercatinib (2) · tazemetostat (2) · tipifarnib (2) · ulixertinib (2) · Bevacizumab (1) · Biopsy (1) · Disulfides (1) · Immunoglobulin G (1)
National Cancer Institute (NCI) (8) · St. Jude Children's Research Hospital (1)
United States (9) · Puerto Rico (8) · Australia (4) · Canada (3) · New Zealand (1)
Adam S Levy (1) · Andrea T Franson (1) · Christine A Pratilas (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Kieuhoa T Vo (1) · Rajen Mody (1) · Sara Federico, MD (1) · Susan N Chi (1)
PMID 31401903, PMID 33591402, PMID 35353553, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (8), U10CA098543 (1)